Related Experiment Video
Updated: Apr 17, 2026
10:03
Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
Published on: August 15, 2025
981
Hypoglycemic activity evaluation and chemical study on hollyhock flowers
Yi Zhang1, Lijun Jin2, Qiu Chen3
1Tianjin State Key Laboratory of Modern Chinese Medicine, 312 Anshanxi Road, Nankai District, Tianjin 300193, PR China.
Fitoterapia
|February 14, 2015
Summary
Hollyhock flower extract significantly lowered blood sugar and triglyceride levels in mice. Its compounds, dihydroflavonol glycosides, enhanced glucose uptake in liver cells, suggesting a potential anti-diabetic effect.
Area of Science:
- Pharmacology and Traditional Medicine
- Biochemistry and Molecular Biology
- Natural Product Chemistry
Background:
- Hollyhock (Althaea rosea) is a perennial garden plant with traditional use in Chinese medicine for diabetes.
- Hyperlipidemia and hyperglycemia are key metabolic dysfunctions associated with type 2 diabetes.
- Understanding the molecular mechanisms of traditional remedies is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the anti-diabetic effects of ethanolic hollyhock flower extract (HFE) in a mouse model.
- To identify and characterize active compounds from HFE responsible for glucose metabolism regulation.
- To elucidate the molecular pathways involved in HFE's glucose-lowering effects.
Main Methods:
- Oral administration of HFE to KK-A(y) mice for 8 weeks.
- Analysis of serum triglyceride and glucose levels.
- Quantitative real-time PCR to assess gene expression (AMPK, IRS2, PI3K, AKT, GLUT4) in liver tissue.
- Isolation and structural elucidation of compounds from HFE using chemical and spectroscopic methods.
- In vitro hepatic cell glucose uptake assay using 2-NBDG in HepG2 cells.
Main Results:
- HFE administration significantly reduced serum triglyceride and glucose levels in KK-A(y) mice.
- Gene expression of AMPK, IRS2, PI3K, AKT, and GLUT4 in the liver was significantly upregulated by HFE.
- Three new dihydroflavonol glycosides (roseaflavanonolosides A-C) and two known compounds were isolated.
- The isolated compounds (1-5) demonstrated a 30%-40% increase in glucose uptake in HepG2 cells at 20 μg/mL.
Conclusions:
- Ethanolic hollyhock flower extract exhibits significant anti-diabetic properties by improving glucose and lipid metabolism in mice.
- The observed effects are associated with the upregulation of key genes involved in insulin signaling and glucose transport.
- Dihydroflavonols present in hollyhock flower are likely responsible for the observed glucose metabolism regulation.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
914
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
914
01:26Hypoglycemia
2
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
2
01:15Hypoglycemia and Glucagon
1.4K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
01:06Oral Hypoglycemic Agents: Glinides
996
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
996
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
994
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
994
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K